Sotatercept (Winrevair, Merck Sharp & Dohme) is 'indicated in combination with other pulmonary arterial hypertension (PAH) therapies for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity'.
The dosage schedule is available in the summary of product characteristics for sotatercept.
The list price of sotatercept is £5,422.50 for a 45-mg vial and £7,230.00 for a 60-mg vial (excluding VAT, BNF online accessed March 2026).
The company has a commercial arrangement. This makes sotatercept available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, MSD's Carbon Reduction Plan for UK carbon emissions is published on MSD's webpage on responsibility.